Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2

OBJECTIVES: Determine the impact of 24-week risankizumab (RZB) versus placebo (PBO) on patient-reported outcomes (PROs) in patients with psoriatic arthritis (PsA) and inadequate response to one or two biologics (Bio-IR) and/or ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-I...

Descripción completa

Detalles Bibliográficos
Autores principales: Ostor, Andrew J K, Soliman, Ahmed M, Papp, Kim A, Padilla, Byron, Wang, Zailong, Eldred, Ann, de Vlam, Kurt, Kivitz, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198792/
https://www.ncbi.nlm.nih.gov/pubmed/35701011
http://dx.doi.org/10.1136/rmdopen-2022-002286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198792/
https://www.ncbi.nlm.nih.gov/pubmed/35701011
http://dx.doi.org/10.1136/rmdopen-2022-002286

Ejemplares similares